Document Detail


Review article: the opportunities and benefits of extended acid suppression.
MedLine Citation:
PMID:  16700900     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acid suppression therapy with proton pump inhibitors is associated with well-established benefits in the management of gastro-oesophageal reflux (GERD) and other acid-related disorders. However, a number of issues still remain unsettled. Despite their clinical efficacy, when given once daily, currently available proton pump inhibitors may not adequately control intragastric acidity during the night in a significant proportion of both healthy subjects and GERD patients, in whom symptom relief remains suboptimal. Although some novel proton pump inhibitors have been synthesized, only few reached clinical testing. Amongst them, tenatoprazole represents a true advance displaying a long half-life (five to seven times longer than that of currently available drugs) and extended acid suppression covering both day and night. All the available clinical studies suggest both pharmacokinetic and pharmacodynamic advantages of tenatoprazole over esomeprazole. As this last compound provides - amongst the members of the class - the most effective control of intragastric pH whatever the parameter considered, it is conceivable that tenatoprazole could similarly be better than the other existing proton pump inhibitors. Tenatoprazole appears to be a promising proton pump inhibitor for the treatment of acid-related diseases, where it has the potential to address unmet clinical needs.
Authors:
C Scarpignato; I Pelosini
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  23 Suppl 2     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-16     Completed Date:  2006-11-09     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  23-34     Citation Subset:  IM    
Affiliation:
Laboratory of Clinical Pharmacology, Department of Anatomy, Pharmacology & Forensic Sciences, School of Medicine & Dentistry, University of Parma, Parma, Italy. scarpi@tin.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antacids / administration & dosage*,  therapeutic use
Anti-Ulcer Agents / administration & dosage*,  therapeutic use
Chemistry, Pharmaceutical
Drug Administration Schedule
Esomeprazole Sodium / administration & dosage,  analogs & derivatives
Gastrointestinal Diseases / drug therapy*
Humans
Imidazoles / administration & dosage
Proton Pumps / antagonists & inhibitors*
Pyridines / administration & dosage
Chemical
Reg. No./Substance:
0/Antacids; 0/Anti-Ulcer Agents; 0/Imidazoles; 0/Proton Pumps; 0/Pyridines; L2C9GWQ43H/Esomeprazole Sodium; RE0689TX2K/Tenatoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review article: acid-related disease--what are the unmet clinical needs?
Next Document:  Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction.